Consolidated revenue amounted to JPY 36,488 million (YoY +23%), operating income was JPY 7,767 million (YoY +37%), and net income attributable to owners of parent was JPY 4,811 million (YoY +28%), showing steady growth.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4483","jir_company_name":"JMDC, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4483-20260205-01.pdf","jir_short_summary":"Consolidated revenue amounted to JPY 36,488 million (YoY +23%), operating income was JPY 7,767 million (YoY +37%), and net income attributable to owners of parent was JPY 4,811 million (YoY +28%), showing steady growth.","jir_summary":"### Performance Overview\nIn the cumulative Q3 of FY2026, consolidated revenue reached JPY 36,488 million (YoY +23%) and consolidated EBITDA was JPY 9,682 million (YoY +27%), maintaining solid growth. The core Health Big Data segment drove performance, with revenue up 26% QoQ and EBITDA up 32%. The Pharmaceutical Sales & Marketing transaction amount increased 43% YoY, contributing to overall revenue expansion. Operating income was JPY 7,767 million (YoY +37%) and net income attributable to owners of parent was JPY 4,811 million (YoY +28%).\n\n### Management Viewpoints and Outlook\nGrowth in the Health Big Data segment continued through Q3, with all businesses demonstrating balanced growth. The utilization of generative AI to create new insights and strategic partnerships with electronic medical record providers are positioned as growth drivers. Progress toward full-year earnings guidance remains on track, and efforts to achieve the target will continue. Plans include strengthening valuable partnerships in response to post-pandemic shifts in market needs.","jir_financial_highlights":"Consolidated Revenue: JPY 36,488 million (YoY +23%)\nConsolidated EBITDA: JPY 9,682 million (YoY +27%)\nOperating Income: JPY 7,767 million (YoY +37%)\nNet Income Attributable to Owners of Parent: JPY 4,811 million (YoY +28%)\nHealth Big Data Revenue: Unknown (QoQ +26%)\nHealth Big Data EBITDA: Unknown (QoQ +32%)\nPharmaceutical Sales & Marketing Transaction Amount: Unknown (YoY +43%)","jir_category":"","jir_hashtags":"#JMDC, #FinancialResultsPresentation, #JapaneseStocks","jir_key_figures":"Consolidated Revenue: JPY 36,488 million (YoY +23%)\nConsolidated EBITDA: JPY 9,682 million (YoY +27%)\nNet Income Attributable to Owners of Parent: JPY 4,811 million (YoY +28%)","jir_meta_title":"JMDC FY2026 Q3 Financial Results Revenue of JPY 36,488 Million Up 23% YoY","jir_meta_description":"JMDC's FY2026 Q3 financial results presentation. Consolidated revenue of JPY 36,488 million (YoY +23%), EBITDA of JPY 9,682 million (+27%), and net income attributable to owners of parent of JPY 4,811 million (+28%) reporting solid growth.","jir_og_title":"JMDC FY2026 Q3 Results Solid 23% Revenue Growth","jir_og_description":"JMDC FY2026 Q3 financial results presentation. Led by the Health Big Data business, both revenue and profit increased significantly YoY.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Consolidated Revenue Quarterly Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"24\/Q1\\\",\\\"24\/Q2\\\",\\\"24\/Q3\\\",\\\"24\/Q4\\\",\\\"25\/Q1\\\",\\\"25\/Q2\\\",\\\"25\/Q3\\\",\\\"25\/Q4\\\",\\\"26\/Q1\\\",\\\"26\/Q2\\\",\\\"26\/Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (Million JPY)\\\",\\\"data\\\":[5779,6756,8233,9803,8096,10451,11075,12099,10725,12355,13407],\\\"borderColor\\\":\\\"#4caf50\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"ebitda_margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Consolidated EBITDA and Margin Quarterly Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"24\/Q1\\\",\\\"24\/Q2\\\",\\\"24\/Q3\\\",\\\"24\/Q4\\\",\\\"25\/Q1\\\",\\\"25\/Q2\\\",\\\"25\/Q3\\\",\\\"25\/Q4\\\",\\\"26\/Q1\\\",\\\"26\/Q2\\\",\\\"26\/Q3\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"EBITDA (Million JPY)\\\",\\\"data\\\":[1603,1563,2831,3215,2831,3138,3312,2267,3256,4157,4157],\\\"borderColor\\\":\\\"#4caf50\\\",\\\"fill\\\":false},{\\\"label\\\":\\\"EBITDA Margin (%)\\\",\\\"data\\\":[34,34,34,34,28,28,28,28,28,28,31],\\\"borderColor\\\":\\\"#ff9800\\\",\\\"fill\\\":false,\\\"yAxisID\\\":\\\"y1\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true},\\\"y1\\\":{\\\"position\\\":\\\"right\\\",\\\"min\\\":0,\\\"max\\\":40}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown (Cumulative Q3)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Health Big Data\\\",\\\"Telemedicine\\\",\\\"Adjustments\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (Million JPY)\\\",\\\"data\\\":[31629,4858,-33],\\\"backgroundColor\\\":[\\\"#4caf50\\\",\\\"#2196f3\\\",\\\"#9e9e9e\\\"]}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":8828,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-24644","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n